MARKET

PRQR

PRQR

ProQR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.04
-0.35
-4.17%
After Hours: 8.04 0 0.00% 16:00 01/17 EST
OPEN
8.38
PREV CLOSE
8.39
HIGH
8.49
LOW
8.00
VOLUME
144.60K
TURNOVER
--
52 WEEK HIGH
16.99
52 WEEK LOW
5.49
MARKET CAP
385.95M
P/E (TTM)
-5.6251
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PRQR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PRQR News

  • Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
  • Zacks.01/06 14:45
  • Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 119%?
  • Simply Wall St..12/23/2019 16:51
  • Did Hedge Funds Drop The Ball On ProQR Therapeutics NV (PRQR) ?
  • Insider Monkey.12/17/2019 22:20
  • ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study
  • Zacks.12/12/2019 20:19

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About PRQR

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
More

Webull offers ProQR Therapeutics NV (PRQR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.